COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic Cholecystectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03713216
Recruitment Status : Completed
First Posted : October 19, 2018
Last Update Posted : July 16, 2020
Information provided by (Responsible Party):
Cathay General Hospital

Brief Summary:
To determine the effect and safety of NALDEBAIN versus Morphine as needed in patients after laparoscopic cholecystectomy.

Condition or disease Intervention/treatment Phase
Pain, Postoperative Drug: Naldebain Drug: Morphine Phase 4

Detailed Description:
This is an open-labeled, randomized clinical trial. Group A will receive one dose of NALDEBAIN before surgery. Group B will receive morphine as needed. Pain will be assessed for PACU, 4, 24, 48, 72 hours after surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic Cholecystectomy
Actual Study Start Date : July 1, 2018
Actual Primary Completion Date : October 1, 2019
Actual Study Completion Date : January 1, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Naldebain
Subjects will receive one dose of Naldebain before surgery.
Drug: Naldebain
150 mg Nalbuphine sebacate

Active Comparator: Morphine
Subjects will receive morphine after surgery.
Drug: Morphine

Primary Outcome Measures :
  1. Postoperative pain score [ Time Frame: 24 hours after surgery ]
    Using visual analog scale (VAS) with grades from 0 (no pain) to 10 (worst pain)

Secondary Outcome Measures :
  1. Consumption of supplemental analgesics [ Time Frame: From Day 0 to Day 3 ]
    Sum of supplemental analgesics

Other Outcome Measures:
  1. Incidence of adverse event [ Time Frame: From Day 0 to Day 3 ]
    Times and incidence of adverse events (injection site reaction, vomiting, nausea, dizziness)

  2. Percentage of Patient satisfaction [ Time Frame: Day 3 ]
    Percentage of patient satisfaction by 5-grade with 'highly satisfied', 'satisfied', 'uncertain', 'dissatisfied' or 'very dissatisfied'.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female with 20 years old or older.
  2. Scheduled to electively undergo laparoscopic cholecystectomy.
  3. Ability and willingness to provide informed consent.

Exclusion Criteria:

  1. Not willing to adhere to the study visit schedule and complete all study assessments.
  2. History of hypersensitivity or allergy to opioid, or NSAIDs or sesame oil.
  3. Any clinically significant condition that may interfere with study assessments or compliance.
  4. Pregnant or breastfeeding.
  5. Medical history may cause abnormal intracranial pressure.
  6. History of dependency, addiction, and withdrawal for narcotic drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03713216

Layout table for location information
Cathay General Hospital
Taipei, Taiwan
Sponsors and Collaborators
Cathay General Hospital
Layout table for investigator information
Principal Investigator: Sing-Ong Lee, MD Cathay General Hospital
Layout table for additonal information
Responsible Party: Cathay General Hospital Identifier: NCT03713216    
Other Study ID Numbers: 402
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: July 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents